Indeed, recent studies indicate enhanced efficacy of anti-amyloid immunotherapies in early AD patients [75, 83] and in individuals with a low brain tau burden, emphasizing the urgency of developing feasible, affordable, and non-invasive techniques for early screening and monitoring of AD. Here, MAPT is linked to Alzheimer disease.